DCC plc Good Growth in First Quarter

DCC plc

DCC plc (LON: DCC), the leading international sales, marketing and support services group, has today issued a Interim Management Statement in advance of the Company’s AGM to be held in Dublin at 11.00 am today.

First quarter ended 30 June 2019
DCC traded in line with expectations and delivered good growth in Group operating profit for the first quarter ended 30 June 2019, driven by acquisitions completed in the prior year.

Year ending 31 March 2020

DCC’s profits are significantly weighted towards the second half of its financial year. At what is still a very early stage in the financial year, the Group reiterates its belief that the year ending 31 March 2020 will be another year of profit growth and development.

Development activity

DCC Technology recently completed the acquisitions of Comm-Tec in Germany and Amacom in the Netherlands, following receipt of customary regulatory approvals. Both Comm-Tec and Amacom will significantly enhance DCC Technology’s service offering in Continental Europe and will strengthen its relationships with suppliers and customers in the region.

DCC Retail & Oil also recently finalised the creation of a new branded aviation fuels marketing and distribution business in Denmark with Shell Aviation, which involved Shell Aviation purchasing an interest in DCC’s existing Danish aviation fuels business.

Further detail regarding each of the above transactions is included in DCC’s Development Update announcement of 14 May 2019.

DCC has grown substantially in recent years and now has significant operations across 18 countries, with market-leading positions in each of its LPG, Retail & Oil, Technology and Healthcare divisions. DCC’s ambition and capacity for further development, together with the Group’s leading market positions and increased geographic reach, provide substantial opportunity for the continued growth and development of the business.

Disposal

DCC Vital recently entered into an agreement to dispose of its UK generic pharma activities and related manufacturing facility in Ireland (Kent Pharma and Athlone Laboratories), subject to regulatory and other consents. The disposal will sharpen the strategic focus of DCC Vital, allowing it to concentrate on those areas where it has market leading positions and sustainable competitive advantage, in particular in the sales, marketing and distribution of medical products in Britain and Ireland. DCC Vital will also continue to develop its pharma activities in Ireland which encompass a market leadership position in the procurement and sales of Exempt Medicinal Products and agency distribution into the hospital and retail pharmacy segments.

Forthcoming events

DCC plc expects to announce its interim results for the six months ending 30 September 2019 on Tuesday 12 November 2019.

Share on:
Find more news, interviews, share price & company profile here for:

    Global Opportunities Trust reports 11.9% one year share price return to 31 August

    Global Opportunities Trust has released its August 2025 factsheet, reporting a 12-month NAV increase of 8.8% and a share price gain of 11.8%.

    Dekel Agri-Vision reports 24.5% revenue growth and break-even net profit in H1 2025

    Dekel Agri-Vision posted a stronger performance for the six months ended 30 June 2025, with Group revenue up 24.5% to €23.9m and EBITDA rising 10.7% to €3.1m.

    Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

    Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event.

    Quadrise signs addendum with Valkor to re-phase payments and MMU deliveries

    Quadrise has agreed an addendum to its Site License and Supply Agreement with Valkor Technologies in Utah. The revised terms re-phase the US$1.0 million licence fee through to June 2026 and adjust delivery schedules for Multifuel Manufacturing Units.

    Ampeak Energy reports interim results and financial close of first battery project

    Ampeak Energy has published its unaudited interim results for the six months ended 30 June 2025. The Group focused on achieving financial close of the 240 MWh AW1 battery project at Uskmouth, which was completed in August 2025.

    Nuformix to present NXP002 data at ERS Congress 2025

    Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic pulmonary fibrosis.

      Search

      Search